Latent diabetes most commonly refers to Latent Autoimmune Diabetes in Adults (LADA), a form of diabetes mellitus that shares characteristics of both type 1 and type 2 diabetes. It is sometimes called "Type 1.5 diabetes."
Here's a more detailed explanation:
-
Definition and Key Characteristics: LADA is a subtype of autoimmune diabetes that occurs in adults, typically after age 30. It's characterized by:
- The presence of autoantibodies against pancreatic islet cells (similar to type 1 diabetes).
- A slower progression of insulin deficiency compared to type 1 diabetes. Many individuals with LADA initially do not require insulin.
- Often misdiagnosed as type 2 diabetes because of the later age of onset and lack of immediate need for insulin.
-
Autoimmunity: Like type 1 diabetes, LADA involves an autoimmune attack on the insulin-producing beta cells in the pancreas. This is confirmed by the presence of autoantibodies, such as:
- Glutamic acid decarboxylase antibodies (GADA)
- Islet cell antibodies (ICA)
-
Clinical Presentation: People with LADA might initially respond to oral medications, similar to individuals with type 2 diabetes. However, because of the ongoing autoimmune destruction of beta cells, they will eventually require insulin therapy.
-
Distinguishing LADA from Type 1 and Type 2 Diabetes:
Feature LADA Type 1 Diabetes Type 2 Diabetes Age of Onset Typically > 30 years Usually < 30 years Usually > 40 years Autoantibodies Present Present Absent Insulin Need Develops gradually Requires insulin soon after diagnosis May not require insulin, especially initially Insulin Resistance Can be present, but not always the primary factor Minimal Often significant -
Diagnosis: Diagnosis of LADA involves testing for diabetes-related autoantibodies in adults who are not acutely insulin-dependent at the time of diagnosis.
-
Importance of Correct Diagnosis: Accurate diagnosis of LADA is crucial for appropriate management. Unlike type 2 diabetes where lifestyle interventions and oral medications are often the first-line treatment, individuals with LADA require closer monitoring of beta-cell function and earlier initiation of insulin therapy to preserve remaining insulin production.
-
Treatment: Treatment strategies typically involve:
- Monitoring blood glucose levels.
- Lifestyle modifications (diet and exercise).
- Eventually, insulin therapy to control blood sugar levels. The timing of insulin initiation can vary depending on the individual's rate of beta-cell decline.
In summary, LADA is a distinct form of diabetes characterized by autoimmune activity and a slow progression towards insulin dependence, often initially misdiagnosed as type 2 diabetes. Recognizing and properly diagnosing LADA is essential for optimal management and preservation of beta-cell function.
